Applications of molecular imaging

Progress in Molecular Biology and Translational Science

Volumn 95, Issue C, 2010, Pages 237-298

  Galbn, Craig J ^a   Galbn, Stefanie ^a   Van Dort, Marcian E ^a   Luker, Gary D ^a   Bhojani, Mahaveer S ^a   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649232306     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-385071-3.00009-5     Document Type: Chapter

References (278)

1. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 6835 2001 355 365
2. J. Westra, and P.C. Limburg p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis Mini Rev Med Chem 6 8 2006 867 874
3. H. Ben-Bassat Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy Curr Opin Investig Drugs 2 11 2001 1539 1545
4. K. Blease Targeting kinases in asthma Expert Opin Investig Drugs 14 10 2005 1213 1220
5. R. Kumar, V.P. Singh, and K.M. Baker Kinase inhibitors for cardiovascular disease J Mol Cell Cardiol 42 1 2007 1 11
6. B.K. Mueller, H. Mack, and N. Teusch Rho kinase, a promising drug target for neurological disorders Nat Rev Drug Discov 4 5 2005 387 398
7. A. Alizadeh The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes Cold Spring Harb Symp Quant Biol 64 1999 71 78
8. O. Margalit Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications Blood Rev 19 4 2005 223 234
9. D.S. Morris Integrating biomedical knowledge to model pathways of prostate cancer progression Cell Cycle 6 10 2007 1177 1187
10. M. Nishiu Microarray analysis of gene-expression profiles in diffuse large B-cell lymphoma: identification of genes related to disease progression Jpn J Cancer Res 93 8 2002 894 901
11. K. Tschoep Gene expression profiling in sarcomas Crit Rev Oncol Hematol 63 2 2007 111 124
12. I.R. Radford Imatinib. Novartis Curr Opin Investig Drugs 3 3 2002 492 499
13. I. Melnikova, and J. Golden Targeting protein kinases Nat Rev Drug Discov 3 12 2004 993 994
14. I. Melnikova, and J. Golden Apoptosis-targeting therapies Nat Rev Drug Discov 3 11 2004 905 906
15. P.Y. Chun Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma Cancer Res 66 2 2006 981 988
16. M.S. Bhojani Imaging of proteolytic activity using a conditional cell surface receptor Mol Imaging 5 2 2006 129 137
17. L. Zhang Molecular imaging of Akt kinase activity Nat Med 13 9 2007 1114 1119
18. S. Fields, and O. Song A novel genetic system to detect proteinprotein interactions Nature 340 6230 1989 245 246
19. K.E. Luker, and D. Piwnica-Worms Optimizing luciferase protein fragment complementation for bioluminescent imaging of proteinprotein interactions in live cells and animals Methods Enzymol 385 2004 349 360
20. S.W. Michnick Universal strategies in research and drug discovery based on protein-fragment complementation assays Nat Rev Drug Discov 6 7 2007 569 582
21. I. Remy, G. Ghaddar, and S.W. Michnick Using the beta-lactamase protein-fragment complementation assay to probe dynamic proteinprotein interactions Nat Protoc 2 9 2007 2302 2306
22. I. Remy, and S.W. Michnick A highly sensitive proteinprotein interaction assay based on Gaussia luciferase Nat Methods 3 12 2006 977 979
23. I. Remy, and S.W. Michnick Application of protein-fragment complementation assays in cell biology Biotechniques 42 2 2007 p. 137, 139, 141 passim
24. E. Stefan Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo Proc Natl Acad Sci USA 104 43 2007 16916 16921
25. C.H. Contag, and B.D. Ross It's not just about anatomy: in vivo bioluminescence imaging as an eyepiece into biology J Magn Reson Imaging 16 4 2002 378 387
26. L.F. Greer III, and A.A. Szalay Imaging of light emission from the expression of luciferases in living cells and organisms: a review Luminescence 17 1 2002 43 74
27. K.E. Luker Kinetics of regulated proteinprotein interactions revealed with firefly luciferase complementation imaging in cells and living animals Proc Natl Acad Sci USA 101 33 2004 12288 12293
28. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 5573 2002 1655 1657
29. T.O. Chan, S.E. Rittenhouse, and P.N. Tsichlis AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide- dependent phosphorylation Annu Rev Biochem 68 1999 965 1014
30. M. Kovarova Structurefunction analysis of Lyn kinase association with lipid rafts and initiation of early signaling events after Fcepsilon receptor I aggregation Mol Cell Biol 21 24 2001 8318 8328
31. J.N. Contessa Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells Cancer Res 68 10 2008 3803 3809
32. A. Chakravarti, J.S. Loeffler, and N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res 62 1 2002 200 207
33. V. Damiano Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma Clin Cancer Res 11 15 2005 5639 5644
34. H. Dote ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition Cancer Res 65 15 2005 6967 6975
35. G. Lammering Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor Clin Cancer Res 7 3 2001 682 690
36. J.N. Contessa Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy Clin Cancer Res 16 12 2010 3205 3214
37. J.C. Ameisen On the origin, evolution, and nature of programmed cell death: a timeline of four billion years Cell Death Differ 9 4 2002 367 393
38. M.S. Bhojani, B.D. Rossu, and A. Rehemtulla TRAIL and anti-tumor responses Cancer Biol Ther 2 4 Suppl. 1 2003 S71 S78
39. M.O. Hengartner The biochemistry of apoptosis Nature 407 6805 2000 770 776
40. D.W. Nicholson, and N.A. Thornberry Apoptosis. Life and death decisions Science 299 5604 2003 214 215
41. D.W. Nicholson, and N.A. Thornberry Caspases: killer proteases Trends Biochem Sci 22 8 1997 299 306
42. Y. Shi Apoptosome: the cellular engine for the activation of caspase-9 Structure 10 3 2002 285 288
43. B. Laxman Noninvasive real-time imaging of apoptosis Proc Natl Acad Sci USA 99 26 2002 16551 16555
44. K.C. Lee Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy Clin Cancer Res 13 6 2007 1839 1846
45. D. Thormeyer Characterization of lacZ complementation deletions using membrane receptor dimerization Biotechniques 34 2 2003 346 350 3525
46. Z. Zhang, W. Zhu, and T. Kodadek Selection and application of peptide-binding peptides Nat Biotechnol 18 1 2000 71 74
47. J.M. Coppola, B.D. Ross, and A. Rehemtulla Noninvasive imaging of apoptosis and its application in cancer therapeutics Clin Cancer Res 14 8 2008 2492 2501
48. D. Khanna A transgenic mouse for imaging caspase-dependent apoptosis within the skin J Invest Dermatol 130 7 2010 1797 1806
49. B.W. Matthews The structure of E. coli beta-galactosidase C R Biol 328 6 2005 549 556
50. S. Celen Synthesis and evaluation of 18F- and 11C-labeled phenyl-galactopyranosides as potential probes for in vivo visualization of LacZ gene expression using positron emission tomography Bioconjug Chem 19 2 2008 441 449
51. C.E. Olesen Novel methods for chemiluminescent detection of reporter enzymes Methods Enzymol 326 2000 175 202
52. A.D. Smith, and J.P. Trempe Luminometric quantitation of photinus pyralis firefly luciferase and Escherichia coli beta-galactosidase in blood-contaminated organ lysates Anal Biochem 286 1 2000 164 172
53. S.O. Van Poucke, and H.J. Nelis Rapid detection of fluorescent and chemiluminescent total coliforms and Escherichia coli on membrane filters J Microbiol Methods 42 3 2000 233 244
54. S.S. Molloy Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis Trends Cell Biol 9 1 1999 28 35
55. S.E. Reznik, and L.D. Fricker Carboxypeptidases from A to z: implications in embryonic development and Wnt binding Cell Mol Life Sci 58 1213 2001 1790 1804
56. R. Vassar Beta-secretase (BACE) as a drug target for Alzheimer's disease Adv Drug Deliv Rev 54 12 2002 1589 1602
57. R. Vassar Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 286 5440 1999 735 741
58. J.M. Coppola A small-molecule furin inhibitor inhibits cancer cell motility and invasiveness Neoplasia 10 4 2008 363 370
59. J.M. Coppola Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity Anal Biochem 364 1 2007 19 29
60. T.O. Ishikawa, and H.R. Herschman Conditional bicistronic Cre reporter line expressing both firefly luciferase and beta-galactosidase Mol Imaging Biol 2010
61. H. Carlsen In vivo imaging of NF-kappa B activity J Immunol 168 3 2002 1441 1446
62. A.H. Lin Global analysis of Smad2/3-dependent TGF-beta signaling in living mice reveals prominent tissue-specific responses to injury J Immunol 175 1 2005 547 554
63. M. Safran Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production Proc Natl Acad Sci USA 103 1 2006 105 110
64. B.R. Rosen Perfusion imaging with NMR contrast agents Magn Reson Med 14 2 1990 249 265
65. P.S. Tofts, and A.G. Kermode Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts Magn Reson Med 17 2 1991 357 367
66. H.C. Schwickert Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy Radiology 198 3 1996 893 898
67. F.C. Su Temporal resolving power of perfusion- and BOLD-based event-related functional MRI Med Phys 31 1 2004 154 160
68. S. Warach Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging Ann Neurol 37 2 1995 231 241
69. A.C. Guo Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics Radiology 224 1 2002 177 183
70. C. Pierpaoli, and P.J. Basser Toward a quantitative assessment of diffusion anisotropy Magn Reson Med 36 6 1996 893 906
71. P.J. Basser, and C. Pierpaoli Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI J Magn Reson B 111 3 1996 209 219
72. J. Gellermann Methods and potentials of magnetic resonance imaging for monitoring radiofrequency hyperthermia in a hybrid system Int J Hyperthermia 21 6 2005 497 513
73. A.G. Sorensen Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging Radiology 199 2 1996 391 401
74. D. Le Bihan Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging Radiology 168 2 1988 497 505
75. M.E. Moseley Diffusion-weighted MR imaging of anisotropic water diffusion in cat central nervous system Radiology 176 2 1990 439 445
76. D. Le Bihan Diffusion and perfusion magnetic resonance imaging in brain tumors Top Magn Reson Imaging 5 1 1993 25 31
77. D. Le Bihan Molecular diffusion nuclear magnetic resonance imaging Magn Reson Q 7 1 1991 1 30
78. M.E. Moseley Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats AJNR Am J Neuroradiol 11 3 1990 423 429
79. E. Stejskal, and J. Tanner Spin diffusion measurements: spin echoes in the presence of a time-dependent field gradient J Chem Phys 42 1 1965 288 292
80. C. Thomsen, O. Henriksen, and P. Ring In vivo measurement of water self diffusion in the human brain by magnetic resonance imaging Acta Radiol 28 3 1987 353 361
81. K.D. Merboldt MRI of "diffusion" in the human brain: new results using a modified CE-FAST sequence Magn Reson Med 9 3 1989 423 429
82. R. Bammer Basic principles of diffusion-weighted imaging Eur J Radiol 45 3 2003 169 184
83. A.R. Padhani Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations Neoplasia 11 2 2009 102 125
84. D. Le Bihan The 'wet mind': water and functional neuroimaging Phys Med Biol 52 7 2007 R57 R90
85. R.R. Edelman, P. Wielopolski, and F. Schmitt Echo-planar MR imaging Radiology 192 3 1994 600 612
86. J.M. Provenzale Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging Radiology 232 2 2004 451 460
87. T. Yoshikawa ADC measurement of abdominal organs and lesions using parallel imaging technique AJR Am J Roentgenol 187 6 2006 1521 1530
88. D.M. Koh Colorectal hepatic metastases: quantitative measurements using single-shot echo-planar diffusion-weighted MR imaging Eur Radiol 16 9 2006 1898 1905
89. D.M. Koh Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients AJR Am J Roentgenol 188 4 2007 1001 1008
90. E.M. Charles-Edwards, and N.M. deSouza Diffusion-weighted magnetic resonance imaging and its application to cancer Cancer Imaging 6 2006 135 143
91. T. Takahara Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display Radiat Med 22 4 2004 275 282
92. T. Ichikawa High-b value diffusion-weighted MRI for detecting pancreatic adenocarcinoma: preliminary results AJR Am J Roentgenol 188 2 2007 409 414
93. M. Sumi, Y. Ichikawa, and T. Nakamura Diagnostic ability of apparent diffusion coefficients for lymphomas and carcinomas in the pharynx Eur Radiol 17 10 2007 2631 2637
94. S. Eida Apparent diffusion coefficient mapping of salivary gland tumors: prediction of the benignancy and malignancy AJNR Am J Neuroradiol 28 1 2007 116 121
95. N. Bulakbasi The added value of the apparent diffusion coefficient calculation to magnetic resonance imaging in the differentiation and grading of malignant brain tumors J Comput Assist Tomogr 28 6 2004 735 746
96. J.S. Shimony Quantitative diffusion-tensor anisotropy brain MR imaging: normative human data and anatomic analysis Radiology 212 3 1999 770 784
97. S. Mori Brain white matter anatomy of tumor patients evaluated with diffusion tensor imaging Ann Neurol 51 3 2002 377 380
98. T.L. Chenevert, P.E. McKeever, and B.D. Ross Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging Clin Cancer Res 3 9 1997 1457 1466
99. J.A. Brunberg In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres AJNR Am J Neuroradiol 16 2 1995 361 371
100. H. Lyng, O. Haraldseth, and E.K. Rofstad Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging Magn Reson Med 43 6 2000 828 836
101. T.L. Chenevert Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors J Natl Cancer Inst 92 24 2000 2029 2036
102. T.L. Chenevert, P.C. Sundgren, and B.D. Ross Diffusion imaging: insight to cell status and cytoarchitecture Neuroimaging Clin N Am 16 4 2006 619 632 viiiix
103. B.D. Ross Evaluation of cancer therapy using diffusion magnetic resonance imaging Mol Cancer Ther 2 6 2003 581 587
104. K.C. Lee Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy Clin Cancer Res 13 2 Pt 1 2007 443 450
105. K.C. Lee Dynamic imaging of emerging resistance during cancer therapy Cancer Res 66 9 2006 4687 4692
106. K.C. Lee An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone Cancer Res 67 8 2007 3524 3528
107. D.A. Hamstra The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies Mol Ther 10 5 2004 916 928
108. K.C. Lee Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit Gene Ther 13 2 2006 127 137
109. P. Therasse New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
110. A.G. Sorensen Comparison of diameter and perimeter methods for tumor volume calculation J Clin Oncol 19 2 2001 551 557
111. S. Yoshida Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer Urology 75 2 2010 387 391
112. T.E. Yankeelov Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results Magn Reson Imaging 25 1 2007 1 13
113. M. Uhl Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging Invest Radiol 41 8 2006 618 623
114. N. Tomura Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: possible prediction of treatment response J Comput Assist Tomogr 30 3 2006 496 500
115. R.J. Theilmann Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy Neoplasia 6 6 2004 831 837
116. Y.S. Sun Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging Radiology 254 1 2010 170 178
117. M.I. Schubert Diffusion-weighted magnetic resonance imaging of treatment-associated changes in recurrent and residual medulloblastoma: preliminary observations in three children Acta Radiol 47 10 2006 1100 1104
118. T.K. Rhee Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging J Vasc Interv Radiol 19 8 2008 1180 1186
119. M.D. Pickles Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer Magn Reson Imaging 24 7 2006 843 847
120. T. Okuma Assessment of early treatment response after CT-guided radiofrequency ablation of unresectable lung tumours by diffusion-weighted MRI: a pilot study Br J Radiol 82 984 2009 989 994
121. B.A. Moffat Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response Proc Natl Acad Sci USA 102 15 2005 5524 5529
122. N. Marugami Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging Cardiovasc Intervent Radiol 32 4 2009 638 646
123. Y. Mardor Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging Cancer Res 61 13 2001 4971 4973
124. Y. Mardor Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging J Clin Oncol 21 6 2003 1094 1100
125. Y. Liu Diffusion-weighted imaging in predicting and monitoring the response of uterine cervical cancer to combined chemoradiation Clin Radiol 64 11 2009 1067 1074
126. Y.C. Lin Significant temporal evolution of diffusion anisotropy for evaluating early response to radiosurgery in patients with vestibular schwannoma: findings from functional diffusion maps AJNR Am J Neuroradiol 31 2 2010 269 274
127. E. Liapi Assessment of response of uterine fibroids and myometrium to embolization using diffusion-weighted echoplanar MR imaging J Comput Assist Tomogr 29 1 2005 83 86
128. C. Kremser Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging Strahlenther Onkol 179 9 2003 641 649
129. D.M. Koh Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial Eur Radiol 19 11 2009 2728 2738
130. S. Kim Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck Clin Cancer Res 15 3 2009 986 994
131. S.H. Kim Locally advanced rectal cancer: added value of diffusion-weighted MR imaging in the evaluation of tumor response to neoadjuvant chemo- and radiation therapy Radiology 253 1 2009 116 125
132. H. Kato Head and neck squamous cell carcinoma: usefulness of diffusion-weighted MR imaging in the prediction of a neoadjuvant therapeutic effect Eur Radiol 19 1 2009 103 109
133. I.R. Kamel Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma J Vasc Interv Radiol 18 1 Pt 1 2007 49 56
134. I.R. Kamel The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma J Vasc Interv Radiol 17 3 2006 505 512
135. R. Jain Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker J Neurooncol 96 3 2010 423 431
136. M.A. Jacobs, E.H. Herskovits, and H.S. Kim Uterine fibroids: diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgerypreliminary study Radiology 236 1 2005 196 203
137. Y. Hayashida Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: Initial results Eur Radiol 16 12 2006 2637 2643
138. V.N. Harry Diffusion-weighted magnetic resonance imaging in the early detection of response to chemoradiation in cervical cancer Gynecol Oncol 111 2 2008 213 220
139. D.A. Hamstra Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma Proc Natl Acad Sci USA 102 46 2005 16759 16764
140. C.J. Galban A feasibility study of parametric response map analysis of diffusion-weighted magnetic resonance imaging scans of head and neck cancer patients for providing early detection of therapeutic efficacy Transl Oncol 2 3 2009 184 190
141. A. Dzik-Jurasz Diffusion MRI for prediction of response of rectal cancer to chemoradiation Lancet 360 9329 2002 307 308
142. P. Dirix Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI J Nucl Med 50 7 2009 1020 1027
143. J. Deng Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization J Vasc Interv Radiol 17 7 2006 1195 1200
144. Y. Cui Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases Radiology 248 3 2008 894 900
145. W.M. Byun Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy AJNR Am J Neuroradiol 23 6 2002 906 912
146. C.L. Eccles Change in diffusion weighted MRI during liver cancer radiotherapy: preliminary observations Acta Oncol 48 7 2009 1034 1043
147. P.A. Hein Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury AJNR Am J Neuroradiol 25 2 2004 201 209
148. D.A. Hamstra Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival J Clin Oncol 26 20 2008 3387 3394
149. K.C. Lee A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone Neoplasia 9 12 2007 1003 1011
150. M.A. Zahra Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy Lancet Oncol 8 1 2007 63 74
151. J.P. O'Connor DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents Br J Cancer 96 2 2007 189 195
152. M.L. Ah-See Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer Clin Cancer Res 14 20 2008 6580 6589
153. J. Baar A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers Clin Cancer Res 15 10 2009 3583 3590
154. T.T. Batchelor AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 1 2007 83 95
155. T. Bauerle Imaging anti-angiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis Eur J Radiol 73 2 2010 280 287
156. R.K. Jain Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 6 2009 327 338
157. W.R. Jarnagin Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival Ann Oncol 20 9 2009 1589 1595
158. W.S. Kamoun Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice J Clin Oncol 27 15 2009 2542 2552
159. S. Kim Prediction of response to chemoradiation therapy in squamous cell carcinomas of the head and neck using dynamic contrast-enhanced MR imaging AJNR Am J Neuroradiol 31 2 2010 262 268
160. A.C. Lockhart Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors J Clin Oncol 28 2 2010 207 214
161. T. Meyer A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas Clin Cancer Res 15 13 2009 4484 4492
162. A.G. Sorensen A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 69 13 2009 5296 5300
163. H.W. van Laarhoven Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041) Clin Cancer Res 16 4 2010 1315 1323
164. D. Vriens Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate J Nucl Med 50 11 2009 1777 1784
165. C.I. Wong Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies J Clin Oncol 27 28 2009 4718 4726
166. M.A. Zahra Semiquantitative and quantitative dynamic contrast-enhanced magnetic resonance imaging measurements predict radiation response in cervix cancer Int J Radiat Oncol Biol Phys 74 3 2009 766 773
167. P.S. Tofts Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols J Magn Reson Imaging 10 3 1999 223 232
168. M.O. Leach The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations Br J Cancer 92 9 2005 1599 1610
169. A. Semiz Oysu Dynamic contrast-enhanced MRI in the differentiation of posttreatment fibrosis from recurrent carcinoma of the head and neck Clin Imaging 29 5 2005 307 312
170. Y. Ohno Prognostic value of dynamic MR imaging for non-small-cell lung cancer patients after chemoradiotherapy J Magn Reson Imaging 21 6 2005 775 783
171. M.J. Dobson The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging Clin Radiol 56 2 2001 94 98
172. E.A. Boss Post-radiotherapy contrast enhancement changes in fast dynamic MRI of cervical carcinoma J Magn Reson Imaging 13 4 2001 600 606
173. S.B. Wedam Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer J Clin Oncol 24 5 2006 769 777
174. V. Goh, A.R. Padhani, and S. Rasheed Functional imaging of colorectal cancer angiogenesis Lancet Oncol 8 3 2007 245 255
175. A.F. Shields Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology Mol Imaging Biol 8 3 2006 141 150
176. U. Metser, and E. Even-Sapir Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT Semin Nucl Med 37 3 2007 206 222
177. P. Carmeliet Angiogenesis in health and disease Nat Med 9 6 2003 653 660
178. C. Sturk, and D. Duont Angiogenesis I.F. Tannock, The basic science of oncology 2005 McGraw-Hill New York 231 248
179. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 6 2003 401 410
180. M. Safran, and W.G. Kaelin Jr. HIF hydroxylation and the mammalian oxygen-sensing pathway J Clin Invest 111 6 2003 779 783
181. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 4 2004 581 611
182. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 5 2005 1011 1027
183. W. Renner, and E. Pilger Simultaneous in vivo quantitation of vascular endothelial growth factor mRNA splice variants J Vasc Res 36 2 1999 133 138
184. Y. Sato Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction Ann N Y Acad Sci 902 2000 201 205 discussion 205207
185. N. Ferrara The role of VEGF in the regulation of physiological and pathological angiogenesis Exs 94 2005 209 231
186. C. Rudlowski Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up Int J Gynecol Cancer 16 Suppl. 1 2006 183 189
187. W. Cai PET of vascular endothelial growth factor receptor expression J Nucl Med 47 12 2006 2048 2056
188. A.R. Hsu Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel J Nucl Med 48 3 2007 445 454
189. M. Rodriguez-Porcel Imaging of VEGF receptor in a rat myocardial infarction model using PET J Nucl Med 49 4 2008 667 673
190. W. Cai Positron emission tomography imaging of poststroke angiogenesis Stroke 40 1 2009 270 277
191. C. Chan A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis J Nucl Med 46 10 2005 1745 1752
192. E.H. Danen Integrins: regulators of tissue function and cancer progression Curr Pharm Des 11 7 2005 881 891
193. J.D. Hood, and D.A. Cheresh Role of integrins in cell invasion and migration Nat Rev Cancer 2 2 2002 91 100
194. C.C. Kumar Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis Curr Drug Targets 4 2 2003 123 131
195. E. Ruoslahti Specialization of tumour vasculature Nat Rev Cancer 2 2 2002 83 90
196. W. Cai In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin {alpha}v{beta}3 Cancer Res 66 19 2006 9673 9681
197. W. Cai, and X. Chen Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism Anticancer Agents Med Chem 6 5 2006 407 428
198. Y. Wu microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide J Nucl Med 46 10 2005 1707 1718
199. X. Chen Integrin alpha v beta 3-targeted imaging of lung cancer Neoplasia 7 3 2005 271 279
200. W. Cai A thiol-reactive 18F-labeling agent, N-[2-(4-18F-fluorobenzamido) ethyl]maleimide, and synthesis of RGD peptide-based tracer for PET imaging of alpha v beta 3 integrin expression J Nucl Med 47 7 2006 1172 1180
201. X. Zhang Quantitative PET imaging of tumor integrin alphavbeta3 expression with 18F-FRGD2 J Nucl Med 47 1 2006 113 121
202. A.M. Pendas Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice Mol Cell Biol 24 12 2004 5304 5313
203. S. Wagner Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET Curr Med Chem 13 23 2006 2819 2838
204. O.P. Medina Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide Anticancer Res 25 1A 2005 33 42
205. F.G. Blankenberg Recent advances in the imaging of programmed cell death Curr Pharm Des 10 13 2004 1457 1467
206. M.F. Corsten Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance Cancer Res 66 3 2006 1255 1260
207. C.M. Lahorte Apoptosis-detecting radioligands: current state of the art and future perspectives Eur J Nucl Med Mol Imaging 31 6 2004 887 919
208. J.F. Tait Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods J Nucl Med 47 9 2006 1546 1553
209. S. Rottey Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy J Nucl Med 47 11 2006 1813 1818
210. U. Haberkorn Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone Nucl Med Biol 28 7 2001 793 798
211. C. Bauer 131I-labeled peptides as caspase substrates for apoptosis imaging J Nucl Med 46 6 2005 1066 1074
212. A. Reshef Small-molecule biomarkers for clinical PET imaging of apoptosis J Nucl Med 51 6 2010 837 840
213. I. Madar Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium J Nucl Med 50 5 2009 774 780
214. A. Cohen From the Gla domain to a novel small-molecule detector of apoptosis Cell Res 19 5 2009 625 637
215. L.B. Harrison Impact of tumor hypoxia and anemia on radiation therapy outcomes Oncologist 7 6 2002 492 508
216. J.D. Chapman Hypoxic sensitizersimplications for radiation therapy N Engl J Med 301 26 1979 1429 1432
217. W.A. Denny Prodrug strategies in cancer therapy Eur J Med Chem 36 78 2001 577 595
218. J.G. Rajendran, and D.A. Mankoff Beyond detection: novel applications for PET imaging to guide cancer therapy J Nucl Med 48 6 2007 855 856
219. D. Rischin Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02 J Clin Oncol 24 13 2006 2098 2104
220. J.G. Rajendran Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 18 2006 5435 5441
221. M. Piert Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside J Nucl Med 46 1 2005 106 113
222. R. Beck Pretreatment 18F-FAZA PET Predicts Success of Hypoxia-Directed Radiochemotherapy Using Tirapazamine J Nucl Med 48 6 2007 973 980
223. H. Yuan Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) J Nucl Med 47 6 2006 989 998
224. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 5 2005 341 354
225. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 2 2001 127 137
226. J. Baselga, and L.A. Hammond HER-targeted tyrosine-kinase inhibitors Oncology 63 Suppl. 1 2002 6 16
227. R. Nahta, G.N. Hortobagyi, and F.J. Esteva Growth factor receptors in breast cancer: potential for therapeutic intervention Oncologist 8 1 2003 5 17
228. G. Selvaggi Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer Ann Oncol 15 1 2004 28 32
229. C.J. Witton Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer J Pathol 200 3 2003 290 297
230. A.A. Memon The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients Br J Cancer 94 11 2006 1703 1709
231. I. Velikyan Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors J Nucl Med 46 11 2005 1881 1888
232. R.M. Reilly Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer J Nucl Med 47 6 2006 1023 1031
233. W. Cai Quantitative PET of EGFR expression in xenograft-bearing mice using (64)Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody Eur J Nucl Med Mol Imaging 34 6 2007 850 858
234. A.C. Steffen In vitro characterization of a bivalent anti-HER-2 affibody with potential for radionuclide-based diagnostics Cancer Biother Radiopharm 20 3 2005 239 248
235. A. Orlova Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors J Nucl Med 47 3 2006 512 519
236. T. Engfeldt Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the (99m)Tc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence Eur J Nucl Med Mol Imaging 34 5 2007 722 733
237. P.M. Smith-Jones Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET J Nucl Med 47 5 2006 793 796
238. Z. Levashova SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF Bioconjug Chem 20 4 2009 742 749
239. G. Mariani, P.A. Erba, and A. Signore Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs J Nucl Med 47 12 2006 1904 1907
240. O. Schillaci Somatostatin receptor imaging in patients with neuroendocrine tumors: not only SPECT? J Nucl Med 48 4 2007 498 500
241. L. Bodei, G. Paganelli, and G. Mariani Receptor radionuclide therapy of tumors: a road from basic research to clinical applications J Nucl Med 47 3 2006 375 377
242. J.C. Reubi, and B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 5 2003 781 793
243. M. Ginj Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy Clin Cancer Res 11 3 2005 1136 1145
244. R. Cescato Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists J Nucl Med 47 3 2006 502 511
245. C. Scarpignato, and I. Pelosini Somatostatin analogs for cancer treatment and diagnosis: an overview Chemotherapy 47 Suppl. 2 2001 1 29
246. S.W. Lamberts Somatostatin-receptor imaging in the localization of endocrine tumors N Engl J Med 323 18 1990 1246 1249
247. F. Forrer Neuroendocrine tumors. Peptide receptor radionuclide therapy Best Pract Res Clin Endocrinol Metab 21 1 2007 111 129
248. D. Storch Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0, Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization? J Nucl Med 46 9 2005 1561 1569
249. E.V. Guggenberg Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis J Pharm Sci 93 10 2004 2497 2506
250. M. Gabriel 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 4 2007 508 518
251. E.P. Krenning Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 8 1993 716 731
252. M. Henze Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas J Nucl Med 46 5 2005 763 769
253. G. Meisetschlager Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide J Nucl Med 47 4 2006 566 573
254. C.J. Anderson 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors J Nucl Med 42 2 2001 213 221
255. F.M. Mottaghy, and S.N. Reske Functional imaging of neuroendocrine tumours with PET Pituitary 9 3 2006 237 242
256. J.C. Reubi Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 3 2000 273 282
257. A. Heppeler Receptor targeting for tumor localisation and therapy with radiopeptides Curr Med Chem 7 9 2000 971 994
258. V. Rufini, M.L. Calcagni, and R.P. Baum Imaging of neuroendocrine tumors Semin Nucl Med 36 3 2006 228 247
259. F. Forrer Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC J Nucl Med 46 8 2005 1310 1316
260. M. van Essen Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma J Nucl Med 47 10 2006 1599 1606
261. M. de Jong Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs J Nucl Med 46 Suppl 1 2005 13S 17S
262. M. De Jong Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings Semin Nucl Med 32 2 2002 133 140
263. A.F. Shields Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 11 1998 1334 1336
264. D.A. Mankoff, A.F. Shields, and K.A. Krohn PET imaging of cellular proliferation Radiol Clin North Am 43 1 2005 153 167
265. J. Leyton In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography Cancer Res 66 15 2006 7621 7629
266. F. McLaughlin, and N.B. La Thangue Histone deacetylase inhibitors open new doors in cancer therapy Biochem Pharmacol 68 6 2004 1139 1144
267. J. Leyton Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo Cancer Res 65 10 2005 4202 4210
268. T. Boulikas, and M. Vougiouka Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review) Oncol Rep 11 3 2004 559 595
269. J. Leyton Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging Cancer Res 66 18 2006 9178 9185
270. C. Waldherr Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET J Nucl Med 46 1 2005 114 120
271. Y.J. Yang Use of 3'-deoxy-3'-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors Eur J Nucl Med Mol Imaging 33 4 2006 412 419
272. C.S. Yap Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography Chest 129 2 2006 393 401
273. C. Masters Neuropathology of Alzheimer's disease A. Burns, J. O'Brien, D. Ames, Dememtia 2005 Hodder Arnold London 393 407
274. W.E. Klunk Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 3 2004 306 319
275. K.-J. Lin Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agenta pilot study Nucl Med Biol 37 2010 497 508
276. S.R. Choi Preclinical Properties of 18F-AV-45: a PET imaging agent for mapping beta-amyloid plagues in the brain J Nucl Med 50 2009 1887 1894
277. M. Ono Development of positron-emission tomography/single-photon emission computed tomography imaging probes for in vivo detection of beta-amyloid plaques in Alzheimer's brains Chem Pharm Bull (Tokyo) 57 10 2009 1029 1039
278. M.P. Kung Characterization of IMPY as a potential imaging agent for beta-amyloid plaques in double transgenic PSAPP mice Eur J Nucl Med Mol Imaging 31 8 2004 1136 1145